Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HELP NASDAQ:NBP NYSEAMERICAN:OSTX NASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHELPCybin$5.31-0.6%$5.47$4.29▼$9.83$275.71M0.81.69 million shs617,427 shsNBPI-Mab$2.20-0.9%$2.71$0.85▼$6.79$256.74M1.561.14 million shs395,698 shsOSTXOS Therapies$1.66-2.4%$1.47$1.15▼$2.57$67.21M-1.34776,395 shs299,776 shsPRLDPrelude Therapeutics$4.86-5.6%$3.78$0.75▼$5.54$324.46M1.11578,337 shs505,643 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHELPCybin-3.61%+0.56%+1.71%-10.70%+533,999,900.00%NBPI-Mab-1.33%-10.12%-10.48%-40.00%+221,999,900.00%OSTXOS Therapies-1.73%0.00%+38.21%+25.00%-7.61%PRLDPrelude Therapeutics+6.40%-1.53%+17.05%+137.33%+573.82%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHELPCybin$5.31-0.6%$5.47$4.29▼$9.83$275.71M0.81.69 million shs617,427 shsNBPI-Mab$2.20-0.9%$2.71$0.85▼$6.79$256.74M1.561.14 million shs395,698 shsOSTXOS Therapies$1.66-2.4%$1.47$1.15▼$2.57$67.21M-1.34776,395 shs299,776 shsPRLDPrelude Therapeutics$4.86-5.6%$3.78$0.75▼$5.54$324.46M1.11578,337 shs505,643 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHELPCybin-3.61%+0.56%+1.71%-10.70%+533,999,900.00%NBPI-Mab-1.33%-10.12%-10.48%-40.00%+221,999,900.00%OSTXOS Therapies-1.73%0.00%+38.21%+25.00%-7.61%PRLDPrelude Therapeutics+6.40%-1.53%+17.05%+137.33%+573.82%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHELPCybin 3.17Buy$58.751,006.40% UpsideNBPI-Mab 2.00Hold$9.00309.09% UpsideOSTXOS Therapies 2.33Hold$18.501,014.46% UpsidePRLDPrelude Therapeutics 2.40Hold$7.6757.75% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, PRLD, NBP, and HELP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026OSTXOS Therapies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/4/2026NBPI-Mab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/4/2026PRLDPrelude Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.005/1/2026PRLDPrelude Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/30/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.004/28/2026PRLDPrelude Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold4/27/2026PRLDPrelude Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $8.004/13/2026HELPCybin TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/8/2026NBPI-Mab HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/8/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.003/27/2026OSTXOS Therapies D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHELPCybinN/AN/AN/AN/A$7.89 per shareN/ANBPI-MabN/AN/AN/AN/A$2.00 per shareN/AOSTXOS TherapiesN/AN/AN/AN/A($0.17) per shareN/APRLDPrelude Therapeutics$12.14M25.22N/AN/A$1.09 per share4.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHELPCybin-$81.31M-$4.23N/AN/AN/AN/A-59.98%-50.80%N/ANBPI-Mab-$46.27M-$0.36N/AN/AN/AN/AN/AN/AN/AOSTXOS Therapies-$28.75M-$0.79N/AN/AN/AN/A-6,489.80%-378.94%N/APRLDPrelude Therapeutics-$99.50M-$1.29N/AN/AN/AN/A-129.98%-80.85%N/ALatest OSTX, PRLD, NBP, and HELP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2026Q4 2025NBPI-MabN/A-$0.2990N/A-$0.2990N/AN/A3/31/2026Q4 2025OSTXOS TherapiesN/A-$0.41N/A-$0.41N/AN/A3/10/2026Q4 2025PRLDPrelude Therapeutics-$0.33-$0.20+$0.13-$0.20$20.50 million$5.64 million2/13/2026Q3 2026HELPCybin-$0.53-$0.72-$0.19-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHELPCybinN/AN/AN/AN/AN/ANBPI-MabN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHELPCybinN/A13.7813.78NBPI-MabN/A8.098.09OSTXOS TherapiesN/A0.030.03PRLDPrelude TherapeuticsN/A1.991.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHELPCybin17.94%NBPI-Mab38.38%OSTXOS TherapiesN/APRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipHELPCybin15.00%NBPI-Mab22.10%OSTXOS Therapies10.30%PRLDPrelude Therapeutics63.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHELPCybin5051.63 million43.89 millionN/ANBPI-Mab380115.65 million90.09 millionN/AOSTXOS TherapiesN/A39.53 million35.46 millionN/APRLDPrelude Therapeutics12063.00 million22.74 millionOptionableOSTX, PRLD, NBP, and HELP HeadlinesRecent News About These CompaniesWall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a BetMay 8 at 10:56 AM | zacks.comD Boral Capital initiates coverage of Prelude Therapeutics (PRLD) with buy recommendationMay 5 at 9:20 AM | msn.comPrelude Therapeutics (NASDAQ:PRLD) Now Covered by D. Boral CapitalMay 5 at 3:36 AM | americanbankingnews.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Given Consensus Recommendation of "Hold" by AnalystsMay 4, 2026 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at D. Boral CapitalMay 4, 2026 | marketbeat.comPrelude Therapeutics (PRLD) Projected to Post Earnings on TuesdayMay 3, 2026 | americanbankingnews.comPrelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast CancerMay 1, 2026 | uk.finance.yahoo.com9 Best Biotech Penny Stocks to Buy in 2026April 30, 2026 | insidermonkey.comPrelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks ResearchApril 30, 2026 | marketbeat.comShort Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1%April 29, 2026 | marketbeat.comPrelude Therapeutics (PRLD) price target increased by 19.35% to 6.29April 29, 2026 | msn.comHC Wainwright Issues Positive Estimate for PRLD EarningsApril 29, 2026 | marketbeat.comPrelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock PriceApril 27, 2026 | marketbeat.comPrelude Therapeutics director David P. Bonita acquires $12.5 million in stockApril 24, 2026 | investing.comInsider Buying: Prelude Therapeutics (NASDAQ:PRLD) Director Acquires 2,815,315 Shares of StockApril 24, 2026 | insidertrades.comPrelude Therapeutics (NASDAQ:PRLD) Director Buys $12,499,998.60 in StockApril 23, 2026 | marketbeat.comPrelude Therapeutics (NASDAQ:PRLD) Director David Bonita Buys 2,815,315 SharesApril 23, 2026 | marketbeat.comPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at ...April 20, 2026 | finance.yahoo.comPrelude Therapeutics prices $90M equity offeringApril 20, 2026 | seekingalpha.comPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten OfferingApril 20, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOSTX, PRLD, NBP, and HELP Company DescriptionsCybin NASDAQ:HELP$5.31 -0.03 (-0.56%) Closing price 04:00 PM EasternExtended Trading$5.32 +0.01 (+0.19%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.I-Mab NASDAQ:NBP$2.20 -0.02 (-0.90%) Closing price 04:00 PM EasternExtended Trading$2.21 +0.01 (+0.45%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers. Its product candidates in pre-clinical development stage comprises TJX7, a novel CXCL13 antibody for autoimmune diseases; and TJ-C4GM antibodies for treating oncology diseases. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.OS Therapies NYSEAMERICAN:OSTX$1.66 -0.04 (-2.35%) Closing price 04:10 PM EasternExtended Trading$1.70 +0.04 (+2.41%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.Prelude Therapeutics NASDAQ:PRLD$4.86 -0.29 (-5.63%) Closing price 04:00 PM EasternExtended Trading$4.89 +0.03 (+0.66%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
